Combined ligand based pharmacophore modeling, virtual screening methods to identify critical chemical features of novel potential inhibitors for phosphodiesterase-5

Journal of the Taiwan Institute of Chemical Engineers

Volumn 42, Issue 5, 2011, Pages 709-718

  Chandrasekaran, Meganathan ^a   Sakkiah, Sugunadevi ^a   Lee, Keun Woo ^a  

^a Gyeongsang National University   (South Korea)

Author keywords

HypoGen; Molecular docking; Pharmacophore; Phosphodiesterase 5; Virtual screening

Indexed keywords

HYPOGEN; MOLECULAR DOCKING; PHARMACOPHORE; PHOSPHODIESTERASE-5; VIRTUAL SCREENING;

AMINO ACIDS; DATABASE SYSTEMS; ESTERS; HYDROGEN BONDS; MOLECULAR MODELING; PHARMACODYNAMICS;

THREE DIMENSIONAL;

EID: 80052965617     PISSN: 18761070     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtice.2011.02.012     Document Type: Article

References (44)

1. Alan Salter E., Andrzej W. The Mechanism of Cyclic Nucleotide Hydrolysis in the Phosphodiesterase Catalytic Site. J. Phys. Chem. B 2007, 111:4547.
2. Beavo, J. A., M. D. Houslay, and S. H. Francis, " Cyclic nucleotide phosphodiesterase superfamily," Beavo, J.A., M.D. Houslay, S.H., Francis, (Eds.), CRC Press, Boca Raton, FL, p. 3 (2006).
3. Bi Y., Stoy P., Adam L., He B., Krupinski J., Normandin D., Pongrac R., Seliger L., Watson A., John E.M. Quinolines as Extremely Potent and Selective PDE5 Inhibitors as Potential Agents for Treatment of Erectile Dysfunction. Bioorg. Med. Chem. Lett. 2004, 14:1577.
4. Blokland A., Schreiber R., Prickaerts J. Improving Memory: A Role for Phosphodiesterases. Curr. Pharm. Des. 2006, 12:2522.
5. Brooks B.R., Brucolleri R.E., Olafson B.D., States D.J., Swaminathan S., Karplus M. CHARMM: A Program for Macromolecular Energy, Minimization and Dynamics Calculation. J Comput. Chem. 1983, 4:187.
6. Card G.L., England B.P., Youshinhisa S., Daniel F., Ben P., Byunghun L., Catherine L., Maryam T., Sam G., Ibrahim P.N., Artis D.R., Gideon B., Milburn M.V., Sung-Hou K., Joseph S., Kam Y.J.Z. Structural Basis for the Activity of Drugs that Inhibit Phosphodiesterases. Structure 2004, 12:2233.
7. Chen C.Y.-C. Computational Screening and Design of Traditional Chinese Medicine (TCM) to Block Phosphodiesterase-5. J. Mol. Grap. Mod. 2009, 28:261.
8. Chen C.Y., Chang Y.H., Bau D.T., Huang H.J., Tsai F.J., Tsai C.H., Chian C.Y.C. Ligand-Based Dual Target Drug Design for H1N1: Swine Flu-A Preliminary First Study. J. Biomol. Struct. Dyn. 2009, 27:171.
9. Chen C.Y., Huang H.J., Tsai F.J., Chen C.Y.C. Drug Design for Influenza A Virus Subtype H1N1. J. Taiwan Inst. Chem. Engrs. 2010, 41:8.
10. Chen G., Wang H., Robinson H., Cai J., Wan Y., Ke K. An Insight into the Pharmacophores of Phosphodiesterases-5 Inhibitors from Synthetic and Crystal Structural Studies. Biochem. Pharmacol. 2008, 75:1717.
11. Corbin J.D., Francis S.H., Cyclic GMP Phosphodiesterase-5: Target of Sildenafil. J. Biol. Chem. 1999, 274:13729.
12. Corbin J.D., Francis S.H. Pharmacology of Phosphodiesterases-5 Inhibitors. Int. J. Clin. Pract. 2002, 56:453.
13. Feixas J., Giovannoni M.P., Vergelli C., Gavalda A., Cesari N., Grazianoa A., Dal Piaza V. New pyrazolo[1',5':1 6]pyrimido[4,5-d] pyridazin -4(3H)-ones as Potent and Selective PDE5 Inhibitors. Bioorg. Med. Chem. Lett. 2005, 15:2381.
14. Fischer R. The Principle of Experimentation Illustrated by a Psycho-Physical Expe, Chapter II 1966, Hafner Publishing Co., New York, USA. 8th ed.
15. Flores Toque H.A., Fernanda B.M.P., Cleber E.T., Perissutti E., Fiorino F., Severino B., Frecentese F., Lorenzetti R., Juliana S.B., Santagada V., Caliendo G., Antunes E., De Nucci G. Synthesis and Pharmacological Evaluations of Sildenafil Analogues for Treatment of Erectile Dysfunction. J. Med. Chem. 2008, 51:2807.
16. Francis S.H., Colbran J.L., Mc-Lucas L.M., Corbin J.D. Zinc Interactions and Conserved Motifs of the cGMP-binding cGMP-specific Phosphodiesterase Suggest That It Is a Zinc Hydrolase. J. Biol. Chem. 1994, 269:22477.
17. Giovannoni M.P., Vergelli C., Biancalani C., Cesari N., Graziano A., Biagini P., Gracia J., Gavalda A., Dal Piaz V. Novel Pyrazolopyrimidopyridazinones with Potent and Selective Phosphodiesterase-5(PDE5) Inhibitory Activity as Potential Agents of Treatment of Erectile Dysfunction. J. Med. Chem. 2006, 49:5363.
18. He F., Seryshev A.B., Cowon C.W., Wensel T.G. Multiple Zinc Binding Sites in Retinal Rod cGMP Phosphodiesterase, PDE6αβ. J. Biol. Chem. 2000, 275:20572.
19. Jiang W., Vernon C.A., Qiu Y., Bhattacharjee S., Matthew John T., Haynes-Johnson D., Patricia J.K., Scott G.L., Sui Z. Synthesis and SAR of Tetracyclic Pyrroloquinolones as Phosphodiesterase-5 Inhibitors. Bioorg. Med. Chem. Lett. 2004, 12:1505.
20. Kam Y.J.Z., Graeme L.C., Yoshihisa Suzuki, Richard Artis D., Fong D., Gillette S., Hsieh D., Neiman J., Brian L.W., Zhag C., Michael V.M., Kim S.-H., Schlessinger J., Bollag G. A Glutamine Switches Mechanism for Nucleotide Selectivity by Phosphodiesterases. Mol. Cell 2004, 15:279.
21. Kansal N., Silakari O., Ravikumar M. A Three Dimensional Pharmacophore Modeling for KDR and Tie-2 Receptor Tyrosine Kinase Inhibitors and Virtual Screening for New Mutikinase Inhibitors. QSAR Comb. Sci. 2009, 28:1130.
22. Langer T., Krovat E.M. Chemical Feature-based Pharmacophores and Virtual Library Screening for Discovery of New Leads. Curr. Opin. Drug Dicovery Dev. 2003, 6:370.
23. Lee S.J., Konishi Y., Yu D.T., Miskowski T.A., Riviello C.M., Macina O.T., Frierson M.R., Kondo K., Sugitani M. Discovery of Potent Cyclic GMP Phosphodiesterases Inhibitors. 2-Pyridyl-and 2-Imidazolylquinazolines Possessing Cyclic GMP Phosphodiesterase and Thromboxabe Synthesis Inhibitory Activities. J. Med. Chem. 1995, 38:3547.
24. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings. Adv. Drug. Deliv. Rev. 1997, 23:3.
25. Mehats C., Andersen C.B., Filopnati M., Catherine S.-L.J. Cyclic Nucleotide Phosphodiesterases and Their Role in Endocrine Cell Signaling. Trends Endocrinol. Metab. 2002, 13:29.
26. Palmer M.J., Bell A.S., Fox D.N., Brown D.G. Design of Second Generation Phosphodiesterases-5 Inhibitors. Curr. Top. Med. Chem. 2007, 7:405.
27. Ravikumar M., Pavan S., Bairy S., Pramod A.B., Sumakanth M., Kishore M., Sumithra T. Virtual Screening of Cathepsin k Inhibitors Using Docking and Pharmacophore Models. Chem. Biol. Drug. Des. 2008, 72:79.
28. Rotella D.P. Phosphodiesterase-5 Inhibitors: Current Status and Potential Applications. Nat. Rev. Drug Discov. 2002, 1:674.
29. Rotella D.P., Sun S., Zhu Y., Krupinski J., Pongrac R., Seliger L., Normandin D., John E.M. Optimization of Substituted N-3-Benzylimidazoquinazolinone Sulfonamides as Potent and Selective PDE5 inhibitors. J. Med. Chem. 2000, 43:5037.
30. Smellie A., Kahn S.D., Teig S.L. Analysis of Conformational Coverage. 1.Validation and Estimation of Coverage. J. Chem. Inf. Comput. Sci. 1995, 35:285.
31. Smellie A., Kahn S.D., Teig S.L. An Analysis of Conformational Coverage 2. Applications of Conformational Models. J. Chem. Inf. Comput. Sci. 1995, 35:295.
32. Smellie A., Teig S.L., Towbin P. Poling: Promoting Conformational Variation. J. Comput. Chem. 1995, 16:171.
33. Souness J.E., Aldous D., Sargent C. Immunosuppressive and Anti-inflammatory Effects of Cyclic AMP Phosphodieterase (PDE) type 4 Inhibitors. Immunopharmacology 2000, 47:127.
34. Srivani P., Srinivas E., Raghu R., Narahari Sastry G. Molecular Modeling Studies of Pyridopurinone Derivatives-Potential Phosphodiesterase 5 Inhibitors. J. Mol. Graph. Model. 2007, 26:378.
35. Stehlik J., Movsesian M.A. Inhibitors of Cyclic Nucleotide Phosphodiesterases 3 and 5 as Therapeutic Agents in Heart Failure. Expert Opin. Invest. Drugs 2006, 15:733.
36. Supuran C.T., Mastrolorenzo A., Barbaro G., Scozzafava A. Phosphodiesterase-5 Inhibitors-drug Design and Differentiation Based on Selectivity, Pharmacokinetic and Efficacy Profiles. Curr. Pharm. Des. 2006, 12:3459.
37. Ukita T., Nakamura Y., Kubo A., Yamamoto Y., Takahashi M., Kotera J., Ikeo T. 1-Arylnaphthalene Lignan: A Novel Scaffold for Type 5 Phosphodiesterase Inhibitors. J. Med. Chem. 1999, 42:1293.
38. Vadivelan S., Sinha B.N., Rambabu G., Bappane K., Jagarlapudi S.A.R.P. Pharmacophore Modeling and Virtual Screening Studies to Design Some Potential Histone Deacetylase Inhibitors as New Lead. J. Mol. Graph. Model. 2006, 26:935.
39. Weeks J.L., Zoraghi R., Beasley A., Sekhar K.R., Francis S.H., Corbin J.D. High Biochemical Selectivity of Tadalafil, Sildenafil and Vardenafil for Human Phosphodiesterase 5A1 (PDE5) over PDE11A4 suggests the Absence of PDE11A4 Cross-reaction in Patients. Int. J. Impot. Res. 2005, 17:5.
40. Xia G., Li J., Peng A., Lai S., Zhang S., Shen J., Liu Z., Chen X., Jia R. Synthesis and Phosphodiesterases-5 Inhibitory Activity of novel Pyrido[1 2-e]purin-4(3H)-one derivatives. Bioorg. Med. Chem. Lett. 2005, 15:2790.
41. Yoo H.H., Kim N.S., Im G.J., Kim D.H. Pharmacoinetics and Tissue Distribution of a Novel PDE5 Inhibitors, SK-3530, in rats. Acta Parmacol. Sin. 2007, 28:1247.
42. Yu G., Mason H., Wu X., Wang I., Chong S., Beyer B., Henwood A., Pongrac R., Seliger L., He B., Normandin D., Ferrer P., Zhang R., Adam L., Humphrey W.G., Krupinski J., John E.M. Substituted Pyrazolopyridopyridazines as Orally Bioavailable Potent and Selective PDE5 Inhibitors: Potential Agents for Treatment of Erectile Dysfunction. J. Med. Chem. 2003, 46:457.
43. Zhang J., Liu G., Tang Y. Chemical Function-based Pharmacophore Generation of Selective k-opioid Receptor Agonists by Catalyst and Phase. J. Mol. Model. 2009, 15:1027.
44. Zhu B., Strads S.J. The Novel Functions of cGMP-specific Phosphodiesterases-5 and its Inhibitors in Carcinoma Cells and Pulmonary/cardiovascular Vessels. Curr. Top. Med. Chem. 2007, 7:437.